B.Riley FBR Believes CryoPort (CYRX) Still Has Room to Grow


In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on CryoPort (CYRX), with a price target of $40.00. The company’s shares closed last Thursday at $34.98, close to its 52-week high of $36.78.

According to TipRanks.com, D’silva is a 5-star analyst with an average return of 10.5% and a 47.0% success rate. D’silva covers the Healthcare sector, focusing on stocks such as Cumberland Pharmaceuticals, Eton Pharmaceuticals, and Sensus Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for CryoPort with a $36.00 average price target, implying a 4.6% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $37.00 price target.

See today’s analyst top recommended stocks >>

Based on CryoPort’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $9.77 million and GAAP net loss of $3.94 million. In comparison, last year the company earned revenue of $6.65 million and had a GAAP net loss of $2.39 million.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CYRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts